Schizophrenia: dopamine beta-hydroxylase activity and treatment response.
Cerebrospinal fluid levels of dopamine beta-hydroxylase, found to be relatively constant over time in individual patients, were significantly lower in schizophrenic patients who became nonpsychotic during neuroleptic treatment than in those who remained psychotic. Dopamine beta-hydroxylase activity may delineate a subgroup of patients who have a dopamine-sensitive brain disorder.
D014150:Antipsychotic Agents / Q000627:therapeutic use; D004221:Disulfiram / Q000494:pharmacology; D004299:Dopamine beta-Hydroxylase / Q000134:cerebrospinal fluid* / Q000378:metabolism; D005669:Fusaric Acid / Q000494:pharmacology; D006801:Humans; D007980:Levodopa / Q000009:adverse effects; D012559:Schizophrenia / Q000201:enzymology*
D014150:Antipsychotic Agents; D007980:Levodopa; D004299:Dopamine beta-Hydroxylase; D005669:Fusaric Acid; D004221:Disulfiram